Guillermo Villacampa Javierre - Vall d'Hebron Institute of Oncology

基本信息

Career Trajectory

Bio

G. Villacampa works as biostatistician in the Oncology Data Science group (OdysSey) at Vall d’Hebron Institute of Oncology (VHIO) and in SOLTI group. My main responsibilities in this role are: i) to perform data analysis in clinical research (mainly focus on survival modelling using R software); and ii) to provide guidance in clinical trial designs in oncology. I am a member of the Spanish Biometric Society (SEB), Catalan Statistics Society (SoCE) and Biostatnet.

Research Interests

Papers共 219 篇Author StatisticsCo-AuthorSimilar Experts

By YearBy Citation主题筛选期刊级别筛选合作者筛选合作机构筛选

736P Exceptional Clinical Benefit (ECB) from Immune Checkpoint Inhibitors (icis) in Mismatch-Repair Deficient (mmrd) in Recurrent /metastatic Endometrial Cancer (r/mec): Are We Curing a Subset of MMRd EC Patients (Pts)

J.F. Grau Béjar, T. Guinel, R. Mazzeo,L. Musacchio,O. Le Saux, R. Sabatier, H. Salaun,L. Eberst, C. Garcia Duran, L. Carità,G. Villacampa, J-S. Frenel, G. Scambia, I. Ray-Coquard, D. Lorusso, A. Oaknin, A. Leary

Annals of Oncology (2024)

Cited0Views0Bibtex

LBA3 SOLTI-1507 IPATHER: Primary Results of the Phase Ib Study of Ipatasertib (IPAT) and Dual Anti-Her2 Therapy with Trastuzumab and Pertuzumab (HP) in Patients (pts) with PIK3CA Mutant (mut) HER2+ Advanced Breast Cancer (ABC)

M. Oliveira,E.M. Ciruelos,S. Morales Murillo,F.J. Salvador Bofill,V. Quiroga Garcia,J. Gavilá-Gregori, A.S. Cortegoso Mosquera,E. Vega Alonso,F. Henao,S. Servitja Tormo,P. Tolosa Ortega,G. Villacampa Javierre,F. Salvador, M. Paes Dias,J.M. Ferrero-Cafiero,X. González Farre,T. Pascual,C. Saura Manich

ESMO Open (2024)

Cited0Views0Bibtex

Adjuvant Trastuzumab Emtansine Versus Paclitaxel Plus Trastuzumab for Stage I Human Epidermal Growth Factor Receptor 2–positive Breast Cancer: 5-Year Results and Correlative Analyses from ATEMPT

Paolo Tarantino,Nabihah Tayob,Guillermo Villacampa,Chau Dang,Denise A Yardley,Steven J Isakoff,Vicente Valero,Meredith Faggen,Therese Mulvey,Ron Bose,Douglas Weckstein,Antonio C Wolff,Katherine Reeder-Hayes,Hope S Rugo,Bhuvaneswari Ramaswamy,Dan Zuckerman,Lowell Hart,Vijayakrishna K Gadi,Michael Constantine,Kit Cheng,Audrey Merrill Garrett,P Kelly Marcom,Kathy Albain,Patricia DeFusco,Nadine Tung,Blair Ardman,Rita Nanda,Rachel C Jankowitz,Mothaffar Rimawi,Vandana Abramson,Paula R Pohlmann,Catherine Van Poznak,Andres Forero-Torres,Minetta C Liu,Kathryn J Ruddy,Adrienne G Waks,Michelle DeMeo,Harold J Burstein,Ann H Partridge,Patrizia Dell'Orto,Leila Russo,Emma Krause, Daniel J Newhouse,Busem Binboğa Kurt,Elizabeth A Mittendorf,Bryan Schneider,Aleix Prat,Eric P Winer,Ian E Krop,Sara M Tolaney, Consortium of the TBCRC Translational Investigators, TBCRC Translational Investigators

Journal of clinical oncology official journal of the American Society of Clinical Oncologyno. 31 (2024): 3652-3665

Cited0Views0WOSBibtex

13P HER2DX ERBB2 Mrna Score in First-Line Metastatic HER2-positive (HER2+) Breast Cancer (BC): Implications for Treatment Stratification

R. Sanchez Bayona,O. Martínez-Sáez, D.R. Romero,E. Segui Solis,E. Carcelero,P. Tolosa Ortega, J. Soberino García,M. Alva Bianchi,T. Pascual, A.M. Gaspar,G. Villacampa Javierre,W. Buckingham, M. Marin,L. Pare Brunet,P. Villagrasa Gonzalez,C.M. Perou, J. Maues,A. Prat,F. Brasó-Maristany,E.M. Ciruelos

ESMO Open (2024)

Cited0Views0Bibtex

Abstract PO2-15-06: Ctdna-Based DNADX in Hormone Receptor-Positive and HER2-negative (HR+/HER2-) Advanced Breast Cancer Following Endocrine Therapy and CDK4/6 Inhibition: a Correlative Analysis from the Randomized Phase 2 PARSIFAL Trial

Fara Brasó-Maristany,Javier Cortés,José Manuel Pérez-García, Rosario Vega-León,Laia Paré,Guillermo Villacampa,Judit Matito, Francisco Pardo,Marina Gomez-Rey,Mario Mancino, Elena Martínez-García, Carmen Mora Gallardo,Leonardo Mina,Florence Dalenc,Meritxell Bellet- Ezquerra,Manuel Ruíz - Borrego,Miguel Gil-Gil,Peter Schmid,Charles M. Perou,Joel S. Parker,Patricia Villagrasa,Ana Vivancos,Aleix Prat,Antonio Llombart-Cussac

Cancer Researchno. 9_Supplement (2024): PO2-15

Cited0Views0Bibtex

49P A Ctdna Tool for Identifying ESR1-mutated Biology in ESR1-non-mutated Hormone Receptor-Positive (HR+) Metastatic Breast Cancer (MBC)

I. Garcia Fructuoso,O. Martínez-Sáez, F. Pardo, M.D.R. Vega León,J. Matito,L. Pare Brunet,O. Castillo,G. Villacampa Javierre,P. Galván,J. Odegaard,P. Villagrasa Gonzalez, J. Parker,C.M. Perou,A. Vivancos,A. Prat,F. Brasó-Maristany

ESMO Open (2024)

Cited0Views0Bibtex

268P Impact of B Cell and Plasma Cell Infiltration on Survival in Early-Stage Breast Cancer (BC) Without Recurrence

L. Angelats,L. Pare Brunet, C. Rubio-Perez,E. Sanfeliu Torres,E. Segui Solis,G. Villacampa, M. Marin, B. Conte,O. Martinez Saez, A. Fernandez-Martinez,W. Buckingham,S. Guedan,H. Heyn, A. Vivancos, J. Parker,P. Villagrasa Gonzalez, C.M. Perou, A. Prat,F. Braso Maristany

Annals of Oncology (2024)

Cited0Views0Bibtex

Author Statistics

Co-Author

Co-Institution

D-Core

合作者
学生
导师

No result temporarily, you can search similar Scholar with the same research interest

Data Disclaimer

The page data are from open Internet sources, cooperative publishers and automatic analysis results through AI technology. We do not make any commitments and guarantees for the validity, accuracy, correctness, reliability, completeness and timeliness of the page data. If you have any questions, please contact us by email: report@aminer.cn